Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine.

被引：0
|
作者：
Keating, MJ
Byrd, J
Rai, K
Flinn, I
Jain, V
Binet, JL
Bolin, R
Hillmen, P
Hutchinson, M
机构：
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3118
引用
收藏
页码：705A / 705A
页数：1
相关论文
共 50 条
  • [41] Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    Lundin, J
    Kimby, E
    Björkholm, M
    Broliden, PA
    Celsing, F
    Hjalmar, V
    Möllgård, L
    Rebello, P
    Hale, G
    Waldmann, H
    Mellstedt, H
    Österborg, A
    BLOOD, 2002, 100 (03) : 768 - 773
  • [42] Feasiblity of autologous stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL) patients treated with sequential fludarabine and Campath-1H.
    Tedeschi, A
    Cairoli, R
    Montillo, M
    Marenco, P
    Grillo, G
    Rossi, V
    Cafro, AM
    Intropido, L
    Morra, E
    BLOOD, 2004, 104 (11) : 520A - 520A
  • [43] Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
    Cortelezzi, Agostino
    Vigano, Mauro
    Zilioli, Vittorio R.
    Fantini, Norma N.
    Pasquini, Maria C.
    Deliliers, Giorgio Lambertenghi
    Colombo, Massimo
    Lampertico, Pietro
    JOURNAL OF CLINICAL VIROLOGY, 2006, 35 (04) : 467 - 469
  • [44] Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia
    Nabhan, C
    Rosen, ST
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 75 - 80
  • [45] Maintenance therapy with a monthly injection of Campath-1H in refractory chronic leukemia and NHL patients.
    Thieblemont, C
    Bouafia, F
    Hornez, E
    Hequet, O
    Arnaud, P
    Espinouse, D
    Salles, G
    Coiffier, B
    BLOOD, 2002, 100 (11) : 805A - 805A
  • [46] Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG)
    Stilgenbauer, S
    Kröber, A
    Winkler, D
    Kienle, D
    Busch, R
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
  • [47] Merkel cell cancer (MCC) in a patient with chronic lymphocytic leukemia (CLL) treated with rituximab and fludarabine.
    Ramshesh, P
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (01) : S272 - S273
  • [48] Cytogenetic analysis in 312 patients with chronic B-lymphocytic leukemia (B-CLL)
    Grimoldi, MG
    Benevento, A
    Malgara, R
    Meroni, E
    Ouarantiello, G
    Baldini, L
    Cortelezzi, A
    Coggi, G
    CYTOGENETICS AND CELL GENETICS, 1999, 85 (1-2): : 70 - 70
  • [49] Novel bax mutations in chronic lymphocytic leukemia (B-CLL)
    Moshynska, O
    Sheridan, DP
    Saxena, A
    FASEB JOURNAL, 2001, 15 (04): : A589 - A589
  • [50] VH analysis in familial chronic lymphocytic leukemia (B-CLL).
    Siakantaris, MP
    Kontopidou, FN
    Kyrtsonis, MC
    Vassilakopoulos, TP
    Kokoris, SI
    Dimopoulou, MN
    Dimitriadou, EM
    Angelopoulou, MK
    Pangalis, GA
    BLOOD, 2003, 102 (11) : 670A - 670A
12345